CRISPR Therapeutics AG (CRSP) Interest & Investment Income (2015 - 2026)

CRISPR Therapeutics AG has reported Interest & Investment Income for 7 years, with the latest figure at -$6.7 million in Q1 2026.

• Quarterly Interest & Investment Income fell 398.58% year-over-year to -$6.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.1 million (down 207.82% YoY) and the FY2025 annual result came in at $2.9 million, up 5650.0% from the prior year.
• Interest & Investment Income eased to -$6.7 million in Q1 2026 per CRSP's latest filing, from -$166000.0 in the prior quarter.
• Over five years, Interest & Investment Income peaked at $13.4 million in Q3 2024 and troughed at -$11.8 million in Q1 2022.
• A 5-year average of $182000.0 and a median of -$166000.0 in 2025 frame the typical range for Interest & Investment Income.
• The sharpest annual moves came in 2022 and 2024: Interest & Investment Income sank 2980.68% in 2022, then surged 518.89% in 2024.
• Over 5 years, Interest & Investment Income stood at $6.5 million in 2022, then soared by 33.04% to $8.6 million in 2023, then sank by 199.87% to -$8.6 million in 2024, then soared by 98.08% to -$166000.0 in 2025, then sank by 3954.22% to -$6.7 million in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered -$6.7 million, -$166000.0, and $973000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.